- Poster presentation
- Open Access
Multi-objective de novo adrug design using evolutionary graphs
© Nicolaou and Pattichis 2008
Published: 26 March 2008
Drug discovery and development is a complex, lengthy process and failure of a candidate molecule can occur as a result of a combination of reasons, such as poor pharmacokinetics, lack of efficacy or toxicity. Drugs compromise the numerous, sometimes competing objectives so that the benefits to patients outweigh potential drawbacks and risks . De novo drug design, involves searching an immense space of feasible, drug-like molecules to select those with the highest chances of becoming drugs using computational technology . Traditionally, de novo design has focused on designing molecules satisfying a single objective, such as a similarity value to a known ligand or a virtual screening score, and ignored the presence of the multiple objectives required for drug-like behavior. Recently, methods have appeared in the literature that attempt to design molecules satisfying multiple predefined objectives . In this presentation we briefly review these methods and then describe a new multi-objective optimization de novo design algorithm that combines evolutionary techniques with graph-theory to directly manipulate molecular graphs and design structurally diverse molecules satisfying one or more objectives.
In our experimental section we present results obtained from applying the method to design molecules with a desired biological profile with the primary constraint based on a set of known ligands. The implementation of the algorithm includes an initial step where the supplied ligand dataset is analyzed to extract and characterize frequently occurring molecular subgraphs. The resulting subgraphs together with other predefined elements form the molecular building blocks used by the algorithm. In subsequent steps a set of initial molecular graphs is prepared and subjected to an evolutionary process that involves fitness calculation against each objective, identification of a compromise surface (also known as Pareto-ranking), parent selection, mutation and crossover. Fitness calculation focuses on pharmacophoric similarity with the known ligands while parent selection uses a graph-based diversity method in order to preserve structural diversity of the evolved molecules. Our findings indicate that the proposed algorithm produces compromising solutions of substantial structural diversity and can thus be used for an efficient search of the pharmacologically interesting chemical space as defined by the supplied ligands and constrained by the objectives defined.
- Nicolaou CA, Brown N, Pattichis C: Molecular optimization using computational multi-objective methods. Curr Opin Drug Discov Dev. 2007, 10 (3): 316-24.Google Scholar
- Schneider G, Fechner U: Computer-based de novo design of druglike molecules. Nat Rev Drug Discov. 2005, 4 (8): 649-663. 10.1038/nrd1799.View ArticleGoogle Scholar
- Brown N, McKay B, Gilardoni F, Gasteiger J: A graph-based genetic algorithm and its application to the multiobjective evolution of median molecules. J Chem Inf Comput Sci. 2004, 44 (3): 1079-1087. 10.1021/ci034290p.View ArticleGoogle Scholar